RSH Stock Overview
An e-health SaaS company, researches, develops, and commercializes medical devices in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Respiri Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.084 |
| 52 Week High | AU$0.084 |
| 52 Week Low | AU$0.021 |
| Beta | 0.24 |
| 11 Month Change | 110.00% |
| 3 Month Change | 211.11% |
| 1 Year Change | 265.22% |
| 33 Year Change | 52.73% |
| 5 Year Change | -3.45% |
| Change since IPO | 170.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSH | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 5.0% | -0.4% | -1.4% |
| 1Y | 265.2% | 14.2% | 16.2% |
Return vs Industry: RSH exceeded the Australian Medical Equipment industry which returned 14.2% over the past year.
Return vs Market: RSH exceeded the Australian Market which returned 16.2% over the past year.
Price Volatility
| RSH volatility | |
|---|---|
| RSH Average Weekly Movement | 13.8% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RSH's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: RSH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marjan Mikel | respiri.co |
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and the United States. The company develops, produces, and sells mobile health applications. Its products include wheezo, a wheeze rate detector; respiri mobile application; and Respiri health portal.
Respiri Limited Fundamentals Summary
| RSH fundamental statistics | |
|---|---|
| Market cap | AU$108.44m |
| Earnings (TTM) | -AU$7.13m |
| Revenue (TTM) | AU$1.04m |
104.4x
P/S Ratio-15.2x
P/E RatioIs RSH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSH income statement (TTM) | |
|---|---|
| Revenue | AU$1.04m |
| Cost of Revenue | AU$3.86k |
| Gross Profit | AU$1.03m |
| Other Expenses | AU$8.16m |
| Earnings | -AU$7.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0055 |
| Gross Margin | 99.63% |
| Net Profit Margin | -686.48% |
| Debt/Equity Ratio | 41.7% |
How did RSH perform over the long term?
See historical performance and comparison